In addition, this scale has also been adopted for other CAR constructs against B-cell maturation antigen (BCMA) for multiple myeloma (MM) [20] and against mesothelin in epithelial ovarian cancer [21]. Here, TNFRSF17 is linked to plasma cell myeloma.